Tumor filoide. Estado del arte

Autores/as

  • Diego Corso Instituto Nacional de Cancerología
  • Daniel Contreras Instituto Nacional de Cancerología
  • Ángel Javier Instituto Nacional de Cancerología
  • Luis Guzmán Instituto Nacional de Cancerología
  • Sandra Díaz Instituto Nacional de Cancerología
  • Oscar García Instituto Nacional de Cancerología
  • Carlos Lehmann Instituto Nacional de Cancerología
  • Mauricio, García Instituto Nacional de Cancerología
  • Carlos Duarte Instituto Nacional de Cancerología
  • Messa Oscar Instituto Nacional de Cancerología

Palabras clave:

Tumor filoide, Neoplasias de la mama, Clasificación, Patología, Cirugía, Quimioterapia, Radioterapia

Resumen

El tumor filoide (TF) es una neoplasia fibroepitelial con una baja incidencia a nivel mundial, lo que limita el poder contar con estudios prospectivos acerca de su abordaje diagnóstico y terapéutico. Se hace una revisión actualizada de su presentación, diagnóstico y tratamiento. Con las características histopatológicas disponibles actualmente se puede subdividir el TF en: de histología benigna, limítrofe y maligna. Esta subclasificación permite establecer el abordaje quirúrgico, que es la base del manejo terapéutico, la indicación de terapias adyuvantes, y finalmente establecer el pronóstico de la paciente.

Biografía del autor/a

Diego Corso, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Daniel Contreras, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Ángel Javier, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Luis Guzmán, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Sandra Díaz, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Oscar García, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Carlos Lehmann, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Mauricio, García, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Carlos Duarte, Instituto Nacional de Cancerología

Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Messa Oscar, Instituto Nacional de Cancerología

Patología Oncológica, Departamento de Patología, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Referencias bibliográficas

Rodríguez Rojas A, Gutierrez R. Revista Colombiana de Cirugía. 1994;9(3):157-62.

Parker SJ, Harries SA. Phyllodes tumours. Postgrad Med J. 2001;77(909):428-35.

https://doi.org/10.1136/pmj.77.909.428

Calhoun KE, Thomas J, Nam Kim J, Lehman CD, Anderson BO. Phyllodes Tumors. En: Harris JR, Lippman ME, Morrow M, Osborne CK, editores. Diseases of the Breast. 4 th Edition ed Lippincott Williams & Wilkins; 2010. p. 782-92.

Belloq JP, Magro G. Fibroepithelial tumours. En: Tavassoli FA, Devilee P, editores. World Health Organisation Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003. p. 99-103.

Huang CC, Liu TP, Cheng SP, Chang YC. Surgical Treatment of Phyllodes Tumor of the Breast with the Trend. Journal of Experimental & Clinical Medicine. 2014;6(5):161-5.

https://doi.org/10.1016/j.jecm.2014.08.002

Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993;71(10):3020-4.

https://doi.org/10.1002/1097-0142(19930515)71:10<3020::AID-CNCR2820711022>3.0.CO;2-G

Abdulcadir D, Nori J, Meattini I, Giannotti E, Boeri C, Vanzi E, et al. Phyllodes tumours of the breast diagnosed as B3 category on image-guided 14-gauge core biopsy: analysis of 51 cases from a single institution and review of the literature. Eur J Surg Oncol. 2014;40(7):859-64.

https://doi.org/10.1016/j.ejso.2014.02.222

Cabrera G, Monduy R, Frías O, Cabrera C. Tumor phyllodes de la mama. Rev Ciencias Médicas. 2011;15(4):22-31.

Orea-Estudillo D, Jaimes-López L, Bernal-Cano J. Tumor phyllodes en un paciente pediátrico. Informe de un caso y revisión de la literatura. Cirugía y Cirujanos. 2008;76(2):165-8.

Lewitan G, Goldberg C, Serro Rde S, Cabaleiro C, Espora SM. [Phyllodes tumor in an 11 years-old girl: Report of a case]. Arch Argent Pediatr. 2010;108(2):e41-3.

Souza JA, Marques EF, Guatelli C, Girão DS, Queroz T, Graziano L, et al. Malignant phyllodes tumor of the breast: case report. Rev Assoc Med Bras. 2011;57(5):495-7.

https://doi.org/10.1590/S0104-42302011000500003

Nagasawa S, Maeda I, Fukuda T, Wu W, Hayami R, Kojima Y, et al. MED12 exon 2 mutations in phyllodes tumors of the breast. Cancer Med. 2015;4(7):1117-21.

https://doi.org/10.1002/cam4.462

Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20(34):4621-8.

https://doi.org/10.1038/sj.onc.1204621

Orribo O, Rodríguez R, Melgar L, Fernández F, De La Torre F. Tumores Phyllodes de mama: clínica, tratamiento y pronóstico. Hospital Universitario de Canarias, España. Rev chil obstet ginecol. 2011;76(6):389-94.

https://doi.org/10.4067/S0717-75262011000600003

Grau AM, Chakravarthy AB, Chugh R. Phyllodes tumours of the breast. En: Rose BD, editor. UpToDate. Waltham, MA: UpToDate; 2014.

Liuzzi J, Fernández A, Velásquez Y, Rincón N. Cistosarcoma phyllodes bilateral un raro caso. Rev venez oncol. 2010;22(3):187-93.

Ibáñez G, Marambio A, Jans J, Gamboa J, Adonis P, Trewhela R, et al. Tumor filoides de la mama*. Rev Chil Cir. 2010;62(2):119-24.

https://doi.org/10.4067/S0718-40262010000200005

Tan H, Zhang S, Liu H, Peng W, Li R, Gu Y, et al. Imaging findings in phyllodes tumors of the breast. Eur J Radiol. 2012;81(1):e62-9.

https://doi.org/10.1016/j.ejrad.2011.01.085

Kamitani T, Matsuo Y, Yabuuchi H, Fujita N, Nagao M, Kawanami S, et al. Differentiation between benign phyllodes tumors and fibroadenomas of the breast on MR imaging. Eur J Radiol. 2014;83(8):1344-9.

https://doi.org/10.1016/j.ejrad.2014.04.031

Ward ST, Jewkes AJ, Jones BG, Chaudhri S, Hejmadi RK, Ismail T, et al. The sensitivity of needle core biopsy in combination with other investigations for the diagnosis of phyllodes tumours of the breast. Int J Surg. 2012;10(9):527-31.

https://doi.org/10.1016/j.ijsu.2012.08.002

Dillon MF, Quinn CM, McDermott EW, O'Doherty A, O'Higgins N, Hill AD. Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery. 2006;140(5):779-84.

https://doi.org/10.1016/j.surg.2006.03.022

Ricci MD, Amaral PG, Aoki DS, Oliveira Filho HR, Pinheiro Wda S, Filassi JR, et al. [Ultrasound-guided core needle biopsy for the diagnosis of fibroepithelial breast tumors]. Rev Bras Ginecol Obstet. 2011;33(1):27-30.

https://doi.org/10.1590/S0100-72032011000100004

Pietruszka M, Barnes L. Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. Cancer. 1978;41(5):1974-83.

https://doi.org/10.1002/1097-0142(197805)41:5<1974::AID-CNCR2820410543>3.0.CO;2-C

Tan PH, Tse G, Lee A, Simpson JF, Harby AM. Fibroepithelial tumours. En: Lakhani SRIOE, Schnitt SJ, Tan PH, van de Vijver MJ, editores. WHO Classification of Tumours of the Breast. 4 th ed. Lyon: IARC; 2012. p. 142-7.

Parfitt JR, Armstrong C, O'malley F, Ross J, Tuck AB. In-situ and invasive carcinoma within a phyllodes tumor associated with lymph node metastases. World J Surg Oncol. 2004;2:46.

https://doi.org/10.1186/1477-7819-2-46

Ghosh P, Saha K. Ductal carcinoma in situ in a benign phyllodes tumor of breast: A rare presentation. J Nat Sci Biol Med. 2014;5(2):470-2.

https://doi.org/10.4103/0976-9668.136261

Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, et al. Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol. 2013;88(2):427-36.

https://doi.org/10.1016/j.critrevonc.2013.06.005

Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Laé M, et al. Management of phyllodes breast tumors. Breast J. 2011;17(2):129-37.

https://doi.org/10.1111/j.1524-4741.2010.01045.x

Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, et al. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol. 2005;91(3):185-94.

https://doi.org/10.1002/jso.20334

Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw. 2007;5(3):324-30.

https://doi.org/10.6004/jnccn.2007.0027

Salvadori B, Cusumano F, Del Bo R, Delledonne V, Grassi M, Rovini D, et al. Surgical treatment of phyllodes tumors of the breast. Cancer. 1989;63(12):2532-6.

https://doi.org/10.1002/1097-0142(19890615)63:12<2532::AID-CNCR2820631229>3.0.CO;2-Q

Zurrida S, Bartoli C, Galimberti V, Squicciarini P, Delledonne V, Veronesi P, et al. Which therapy for unexpected phyllode tumour of the breast? Eur J Cancer. 1992;28(2-3):654-7.

https://doi.org/10.1016/S0959-8049(05)80119-4

Onkendi EO, Jimenez RE, Spears GM, Harmsen WS, Ballman KV, Hieken TJ. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. Ann Surg Oncol. 2014;21(10):3304-9.

https://doi.org/10.1245/s10434-014-3909-x

Barth RJ. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat. 1999;57(3):291-5.

https://doi.org/10.1023/A:1006260225618

Asoglu O, Ugurlu MM, Blanchard K, Grant CS, Reynolds C, Cha SS, et al. Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann Surg Oncol. 2004;11(11):1011-7.

https://doi.org/10.1245/ASO.2004.02.001

Guerrero MA, Ballard BR, Grau AM. Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol. 2003;12(1):27-37.

https://doi.org/10.1016/S0960-7404(03)00005-7

Hashimoto T, Okishiro M, Ishida T, Sato Y, Morimoto Y, Kusama H, et al. [A case of malignant phyllodes tumor after surgery for breast cancer]. Gan To Kagaku Ryoho. 2014;41(12):1927-9.

Mitu's J, Reinfuss M, Mitu's JW, Jakubowicz J, Blecharz P, Wysocki WM, et al. Malignant phyllodes tumor of the breast: treatment and prognosis. Breast J. 2014;20(6):639-44.

https://doi.org/10.1111/tbj.12333

Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107(9):2127-33.

https://doi.org/10.1002/cncr.22228

August DA, Kearney T. Cystosarcoma phyllodes: mastectomy, lumpectomy, or lumpectomy plus irradiation. Surg Oncol. 2000;9(2):49-52.

https://doi.org/10.1016/S0960-7404(00)00022-0

Abdalla HM, Sakr MA. Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast. J Egypt Natl Canc Inst. 2006;18(2):125-33.

Kapiris I, Nasiri N, A'Hern R, Healy V, Gui GP. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol. 2001;27(8):723-30.

https://doi.org/10.1053/ejso.2001.1207

Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer. 2000;89(7):1502-11.

https://doi.org/10.1002/1097-0142(20001001)89:7<1502::AID-CNCR13>3.0.CO;2-P

Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998-2009. Ann Surg Oncol. 2014;21(4):1222-30.

https://doi.org/10.1245/s10434-013-3395-6

Barth RJ, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009;16(8):2288-94.

https://doi.org/10.1245/s10434-009-0489-2

Hawkins RE, Schofield JB, Wiltshaw E, Fisher C, McKinna JA. Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. Cancer. 1992;69(9):2271-5.

https://doi.org/10.1002/1097-0142(19920501)69:9<2271::AID-CNCR2820690911>3.0.CO;2-7

Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez- Basave HN, Gallardo D, Hortobagyi GN, et al. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. Breast J. 2007;13(6):551-6.

https://doi.org/10.1111/j.1524-4741.2007.00510.x

Sapino A, Bosco M, Cassoni P, Castellano I, Arisio R, Cserni G, et al. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol. 2006;19(4):599-606.

https://doi.org/10.1038/modpathol.3800574

Wang H, Wang X, Wang CF. Comparison of clinical characteristics between benign borderline and malignant phyllodes tumors of the breast. Asian Pac J Cancer Prev. 2014;15(24):10791-5.

https://doi.org/10.7314/APJCP.2014.15.24.10791

Lightner AL, Shurell E, Dawson N, Omidvar Y, Foster N. A singlecenter experience and review of the literature: 64 cases of phyllodes tumors to better understand risk factors and disease management. Am Surg. 2015;81(3):309-15.

Cómo citar

[1]
Corso, D., Contreras, D., Javier, Ángel, Guzmán, L., Díaz, S., García, O., Lehmann, C., García, M., Duarte, C. y Oscar, M. 2016. Tumor filoide. Estado del arte. Revista Colombiana de Cancerología. 20, 2 (jun. 2016), 79–86.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

2016-06-01

Número

Sección

Artículos de revisión